Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of nal-irinotecan + 5-fluorouracil/leucovorin, gemcitabine + nab-paclitaxel, or sequential alternating treatment in metastatic pancreatic cancer
2017-004309-41Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Apr 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposomal, fluorouracil, folinic acid, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (3 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Rate of patients alive without progression at 6 months. Started Apr 2018; status: active.
02
Drugs
irinotecan liposomalfluorouracilfolinic acidgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2017-004309-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004309-41.